SD Biosensor에스디바이오센서
137310 · KOSPI · ₩137310 · 에스디바이오센서
- Market cap
- ₩766B
- Enterprise value
- ₩720B
- P/E
- —
- P/B
- 0.3×
- Dividend yield
- 3.2%
- ROE
- −30.4%
- Net margin
- −98.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−37.8% from the high
₩5,800Today: ₩6,310 – ₩6,560₩10,190
Returns
- 1W−6.8%
- 1M+4.4%
- 3M+3.8%
- 6M−25.4%
- YTD−28.8%
- 1Y−36.7%
- Volume today
- 116,805
- 0.8× the 20-day average
- Traded today
- ₩750M
- Listed shares
- 120,749,102
- EPS (12 months)
- −₩6,041
- Earnings yield −95.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- MomentumFlat3.8% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Futures and options
All stock futures →Futures (2026-11): 6,370
Basis +0.47% · implied rate +10.8%
Open interest 16,786 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
SD Biosensor stock overview
SD Biosensor (에스디바이오센서, KRX: 137310) is listed on KOSPI, in the Medical & precision devices sector. The company develops and sells in vitro diagnostic (IVD) medical devices and reagents for infectious and chronic disease testing. Its shares closed at ₩6,340 on Oct 27, 2026, down 2.01% on the day, giving it a market value of ₩766B.
Key facts
- Market cap
- ₩766B
- Sector
- Medical & precision devices
- Latest price change
- −2.01%
- As of
- Oct 27, 2026
- Main business
- The company develops and sells in vitro diagnostic (IVD) medical devices and reagents for infectious and chronic disease testing.
Quick answers about SD Biosensor
- What does SD Biosensor do?
- The company develops and sells in vitro diagnostic (IVD) medical devices and reagents for infectious and chronic disease testing. Its main product lines include rapid point-of-care immunodiagnostic tests (STANDARD Q), fluorescence immunoassay instrument platforms (STANDARD F), ELISA-based tuberculosis tests (STANDARD E), PCR molecular diagnostics (STANDARD M and M10), HbA1c clinical chemistry (STANDARD C), and self-monitoring blood glucose systems (BGMS), serving hospitals, clinical laboratories, public procurement programs and individual users. It holds global certifications such as WHO PQ and CE-IVD and has manufacturing facilities in South Korea, India and Indonesia.
- What is the market cap of SD Biosensor?
- The market capitalisation of SD Biosensor was ₩766B at the close on Oct 27, 2026.
- Who are the largest shareholders of SD Biosensor?
- According to the latest official filings, the largest reported holders are Jo Yeong-sik (72.50%, as of Aug 20, 2026); National Pension Service (4.49%, as of Dec 31, 2025); Lee Hyo-geun (3.47%, as of Mar 16, 2026).
- When is the next earnings report from SD Biosensor?
- Korean companies rarely announce results dates in advance. Based on when SD Biosensor filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own SD Biosensor?
- Yes. The National Pension Service held 4.49% of SD Biosensor shares as of Dec 31, 2025.
Company profile
The company develops and sells in vitro diagnostic (IVD) medical devices and reagents for infectious and chronic disease testing. Its main product lines include rapid point-of-care immunodiagnostic tests (STANDARD Q), fluorescence immunoassay instrument platforms (STANDARD F), ELISA-based tuberculosis tests (STANDARD E), PCR molecular diagnostics (STANDARD M and M10), HbA1c clinical chemistry (STANDARD C), and self-monitoring blood glucose systems (BGMS), serving hospitals, clinical laboratories, public procurement programs and individual users. It holds global certifications such as WHO PQ and CE-IVD and has manufacturing facilities in South Korea, India and Indonesia.
Written by AI from the company's latest annual report.
- Korean name
- 에스디바이오센서
- Themes
- Medical devices
- CEO
- 이효근
- Founded
- Dec 2010
- Listed
- Jul 2021
- Listed shares
- 120,749,102
- Fiscal year ends
- Month 12
- Website
- sdbiosensor.co.kr/
Similar companies
- TSE131290 · ₩2.9T₩260,000+7.88%
- Kctech281820 · ₩1.8T₩91,900+6.37%
- Classys214150 · ₩1.7T₩26,500−2.57%
- Park Systems140860 · ₩1.6T₩225,500+1.12%
- Curiox Biosystems445680 · ₩1.1T₩62,300+6.13%
- DI003160 · ₩1.1T₩37,800+4.71%
- Seers458870 · ₩1T₩26,300−5.57%
- LivsMed491000 · ₩937B₩37,100+1.50%
Recent filings
See all- Corporate value-up planOct 28, 2026
- Corporate value-up planOct 22, 2026
- Insider shareholding reportSep 22, 2026
- 5%+ holding reportAug 20, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: SD Biosensor / 에스디바이오센서 / 137310 / KRX:137310
Source: KRX statistical information